Cargando…
Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-ena...
Autores principales: | Sanchez-Ponce, Raymundo, Wang, Li-Quan, Lu, Wei, von Hehn, Jana, Cherubini, Maryann, Rush, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901214/ https://www.ncbi.nlm.nih.gov/pubmed/24957649 http://dx.doi.org/10.3390/metabo2030596 |
Ejemplares similares
-
A MEG Study of Acute Arbaclofen (STX-209) Administration
por: Roberts, Timothy P. L., et al.
Publicado: (2019) -
Mechanisms that Determine the Differential Stability of Stx(+) and Stx(−) Lysogens
por: Colon, Michael P., et al.
Publicado: (2016) -
Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers
por: Khan, Washim, et al.
Publicado: (2022) -
The GABAB receptor agonist STX209 reverses the autism-like behaviour in an animal model of autism induced by prenatal exposure to valproic acid
por: Jiang, Shucai, et al.
Publicado: (2022) -
Pharmacokinetic Alteration of Baclofen by Multiple Oral Administration of Herbal Medicines in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2014)